Cargando…
Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway
There were approximately 1.93 million new cases and 940 000 deaths from colorectal cancer in 2020. The first‐line chemotherapeutic drugs for colorectal cancer are mainly based on 5‐fluorouracil, although the use of these drugs is limited by the development of drug resistance. Consequently, there is...
Autores principales: | Zhang, Wen, Sun, Ruiqian, Zhang, Yongjun, Hu, Rong, Li, Qian, Wu, Weili, Cao, Xinyu, Zhou, Jiajian, Pei, Jianfeng, Yuan, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564099/ https://www.ncbi.nlm.nih.gov/pubmed/34496154 http://dx.doi.org/10.1002/2211-5463.13290 |
Ejemplares similares
-
Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer
por: Li, Zequn, et al.
Publicado: (2020) -
A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity
por: Yin, Xiaoyi, et al.
Publicado: (2019) -
Preclinical profile of cabazitaxel
por: Vrignaud, Patricia, et al.
Publicado: (2014) -
Antitumor Activity of Cabazitaxel and MSC-TRAIL Derived Extracellular Vesicles in Drug-Resistant Oral Squamous Cell Carcinoma
por: Qiu, Yongle, et al.
Publicado: (2020) -
Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)